These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

434 related items for PubMed ID: 25851122

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Vitamin K Antagonists Compared to Low-Molecular-Weight Heparins for Treatment of Cancer-Associated Venous Thromboembolism: An Observational Study in Routine Clinical Practice. An Observational Study in Routine Clinical Practice.
    den Exter PL, Hooijer J, van der Hulle T, van Oosten JP, Dekkers OM, Klok FA, Huisman MV.
    Thromb Haemost; 2017 Nov 01; 117(11):2163-2167. PubMed ID: 28981552
    [Abstract] [Full Text] [Related]

  • 3. Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer.
    Kahale LA, Hakoum MB, Tsolakian IG, Matar CF, Terrenato I, Sperati F, Barba M, Yosuico VE, Schünemann H, Akl EA.
    Cochrane Database Syst Rev; 2018 Jun 19; 6(6):CD006650. PubMed ID: 29920657
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Impact of anticoagulant choice on hospitalized bleeding risk when treating cancer-associated venous thromboembolism.
    Zakai NA, Walker RF, MacLehose RF, Adam TJ, Alonso A, Lutsey PL.
    J Thromb Haemost; 2018 Dec 19; 16(12):2403-2412. PubMed ID: 30240508
    [Abstract] [Full Text] [Related]

  • 7. Vitamin K antagonists versus low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism.
    Andras A, Sala Tenna A, Stewart M.
    Cochrane Database Syst Rev; 2017 Jul 24; 7(7):CD002001. PubMed ID: 28737834
    [Abstract] [Full Text] [Related]

  • 8. Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer.
    Akl EA, Kahale L, Barba M, Neumann I, Labedi N, Terrenato I, Sperati F, Muti P, Schünemann H.
    Cochrane Database Syst Rev; 2014 Jul 08; (7):CD006650. PubMed ID: 25004410
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Single-center, retrospective evaluation of safety and efficacy of direct oral anticoagulants versus low-molecular-weight heparin and vitamin K antagonist in patients with cancer.
    Pritchard ER, Murillo JR, Putney D, Hobaugh EC.
    J Oncol Pharm Pract; 2019 Jan 08; 25(1):52-59. PubMed ID: 28825375
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Short-term prognosis of breakthrough venous thromboembolism in anticoagulated patients.
    van Es J, Cheung YW, van Es N, Klok FA, Dronkers CEA, Ten Wolde M, Kruip MJHA, Huisman MV, Meijer K, Kamphuisen PW, Gerdes VEA, Middeldorp S.
    Thromb Res; 2020 Mar 08; 187():125-130. PubMed ID: 31986475
    [Abstract] [Full Text] [Related]

  • 14. Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer.
    Akl EA, Labedi N, Barba M, Terrenato I, Sperati F, Muti P, Schünemann H.
    Cochrane Database Syst Rev; 2011 Jun 15; (6):CD006650. PubMed ID: 21678361
    [Abstract] [Full Text] [Related]

  • 15. LMWH in cancer patients with renal impairment - better than warfarin?
    Bauersachs RM.
    Thromb Res; 2016 Apr 15; 140 Suppl 1():S160-4. PubMed ID: 27067971
    [Abstract] [Full Text] [Related]

  • 16. Dose escalation of low molecular weight heparin in patients with recurrent cancer-associated thrombosis.
    Ihaddadene R, Le Gal G, Delluc A, Carrier M.
    Thromb Res; 2014 Jul 15; 134(1):93-5. PubMed ID: 24835673
    [Abstract] [Full Text] [Related]

  • 17. Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism.
    Robertson L, Strachan J.
    Cochrane Database Syst Rev; 2017 Feb 14; 2(2):CD006771. PubMed ID: 28195640
    [Abstract] [Full Text] [Related]

  • 18. Decreased Bleeding Incidence with Direct Oral Anticoagulants Compared to Vitamin K Antagonist and Low-Molecular-Weight Heparin in Patients with Sickle Cell Disease and Venous Thromboembolism.
    Patel A, Williams H, Baer MR, Zimrin AB, Law JY.
    Acta Haematol; 2019 Feb 14; 142(4):233-238. PubMed ID: 31108496
    [Abstract] [Full Text] [Related]

  • 19. Comparison Between Non-vitamin K Antagonist Oral Anticoagulants and Low-Molecular-Weight Heparin in Asian Individuals With Cancer-Associated Venous Thromboembolism.
    Chen DY, Tseng CN, Hsieh MJ, Lan WC, Chuang CK, Pang ST, Chen SW, Chen TH, Chang SH, Hsieh IC, Chu PH, Wen MS, Chen JS, Chang JW, See LC, Huang WK.
    JAMA Netw Open; 2021 Feb 01; 4(2):e2036304. PubMed ID: 33533929
    [Abstract] [Full Text] [Related]

  • 20. Direct Oral Anticoagulants for the Treatment of Acute Venous Thromboembolism Associated with Cancer: A Systematic Review and Meta-Analysis.
    Giustozzi M, Agnelli G, Del Toro-Cervera J, Klok FA, Rosovsky RP, Martin AC, Herold J, Tzoran I, Szmit S, Bertoletti L, Becattini C, Huisman MV.
    Thromb Haemost; 2020 Jul 01; 120(7):1128-1136. PubMed ID: 32365386
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.